ARTICLE | Company News
Epix Medical, Schering deal
May 15, 2000 7:00 AM UTC
Schering received a royalty-bearing license to European Patent No. 222,886 and U.S. Patents Nos. 4,899,755 and 4,880,008 covering MRI contrast agents. The patents are issued to Massachusetts General Hospital and licensed exclusively to EPIX. EPIX said the patents relate to Schering's Eovist gadolinium injection MRI contrast agent, which is in Phase III testing to image the liver. As a result of the license, Schering withdrew its opposition against the European patent. ...